1. Home
  2. FNLC vs TECX Comparison

FNLC vs TECX Comparison

Compare FNLC & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

N/A

Current Price

$28.38

Market Cap

288.7M

Sector

Finance

ML Signal

N/A

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

N/A

Current Price

$17.89

Market Cap

359.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FNLC
TECX
Founded
1864
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
288.7M
359.0M
IPO Year
1999
2018

Fundamental Metrics

Financial Performance
Metric
FNLC
TECX
Price
$28.38
$17.89
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$81.20
AVG Volume (30 Days)
18.4K
296.1K
Earning Date
01-21-2026
11-06-2025
Dividend Yield
5.24%
N/A
EPS Growth
18.07
N/A
EPS
2.81
N/A
Revenue
$88,119,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.06
N/A
Revenue Growth
12.70
N/A
52 Week Low
$22.11
$13.70
52 Week High
$28.47
$61.07

Technical Indicators

Market Signals
Indicator
FNLC
TECX
Relative Strength Index (RSI) 74.11 42.59
Support Level $25.94 $18.60
Resistance Level $26.42 $19.99
Average True Range (ATR) 0.52 1.41
MACD 0.27 -0.32
Stochastic Oscillator 92.92 1.97

Price Performance

Historical Comparison
FNLC
TECX

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: